Note: In lieu of an abstract, this is an excerpt from the first page.
In bacteria, a major resistance mechanism to β-lactam antibiotics is the production of one or more β-lactamase enzymes. β-Lactamases belong to two structurally and mechanistically unrelated families of enzymes, serine-β-lactamases (SBLs; classes A, C, and D) and metallo-β-lactamases (MBLs; class B). The interest in discovering novel inhibitors has recently renewed to counter the threat from newer β-lactamases, such as the extended spectrum β-lactamases (ESBLs) and carbapenemases, that are not inhibited by classical SBL inhibitors. Although resistance development is an ordinary evolutionary process, it has been significantly accelerated by the widespread and uncontrolled misuse of antibiotics and, nowadays, it represents one of the most relevant threats for human health.This Special Issue includes full research articles, brief reports and reviews focused on the targeting of b-lactamases to fight bacterial drug resistance.[...]

中文翻译：

---

特刊社论：“针对β-内酰胺酶以对抗细菌对β-内酰胺抗生素的耐药性”。

注意：代替摘要，这是第一页的摘录。
在细菌中，对β-内酰胺类抗生素的主要耐药机制是产生一种或多种β-内酰胺酶。β-内酰胺酶属于结构和机械上不相关的两个酶家族，即丝氨酸-β-内酰胺酶（SBL； A，C和D类）和金属-β-内酰胺酶（MBL； B类）。最近，人们发现新型抑制剂的兴趣不断增强，以应对来自新型β-内酰胺酶（例如，广谱β-内酰胺酶（ESBLs）和碳青霉烯酶）的威胁，而这些β-内酰胺酶并没有受到经典SBL抑制剂的抑制。尽管耐药性的发展是一个普通的进化过程，但由于滥用抗生素的广泛而不受控制的滥用已大大加速了耐药性的发展，如今，它已成为对人类健康最重要的威胁之一。